References
- Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021 Apr 5;149:778–789.
- Centers for Disease Control and Prevention. Leading causes of death. 2022 [Cited 2022 Sep 1] Available from: https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm
- American Cancer Society. Cancer Facts & Figures. 2022 [Cited 2022 Aug 31] Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html
- Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody–based cancer immunotherapy. Mol Cancer Ther. 2004;3(11):1493–1501.
- Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies (Basel, Switzerland). 2020;9(3):34.
- Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther. 2008 Aug 8;8(8):1151–1158.
- Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021 Jul;20(7):491–495.
- Kaplon H, Chenoweth A, Crescioli S, et al. Antibodies to watch in 2022. MAbs. 2022 Jan-Dec;14(1):2014296.
- Hernandez I, Bott SW, Patel AS, et al. Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care. 2018 Feb;24(2):109–112.
- U.S. Food and Drug Administration. Biosimilars 2022 [Cited 2022 Sep 10]. Available from: https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars
- U.S. Food and Drug Administration. Biosimilar development, review, and approval. 2017 [Cited 2022 Sep 10]. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval#process
- U.S. Food and Drug Administration. Biosimilar product information. 2022 [Cited 2022 Sep 10]. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
- Rhodes W, DeClue RW, Accortt NA, et al. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. Future Oncol. 2021 Dec;17(36):5119–5127.
- Mendes D, Abrantes J, Rigueiro G, et al. Real-world intensive safety monitoring of biosimilars rituximab and trastuzumab in a Portuguese oncology hospital. J Oncol Pharm Pract. 2021 Sep;27(6):1432–1438.
- Pivot X, Pegram M, Cortes J, et al. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. Eur J Cancer. 2019 Oct;120:1–9.
- Booth JP, Pilz J. Retrospective indication-matched cohort study of reference product and biosimilar: bevacizumab versus bevacizumab-awwb. Hosp Pharm. 2022 Aug;57(4):455–461.
- U.S. Food and Drug Administration. Questions and answers on FDA’s Adverse Event Reporting System (FAERS) 2018 [Cited 2022 Sep 11]. https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers
- U.S. Food and Drug Administration. Purple book: lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. 2020 [Cited 2022 Sep 11]. Available from: https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/purple-book-lists-licensed-biological-products-reference-product-exclusivity-and-biosimilarity-or
- U.S. Food and Drug Administration. Biosimilar product information. 2022 [Cited 2022 Sep 11]. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
- U.S. Food and Drug Administration. Nonproprietary naming of biological products guidance for industry. 2019 [Cited 2022 Sep 11]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonproprietary-naming-biological-products-guidance-industry
- U.S. Food and Drug Administration. What is a serious adverse event? 2016 [Cited 2022 Sep 11]. Available from: https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event
- BioPortal. Medical Dictionary for Regulatory Activities Terminology (MedDRA). 2022 [Cited 2022 Sep 11]. Available from: https://bioportal.bioontology.org/ontologies/MEDDRA
- Alexeev SM, Khorinko AV, Mukhametshina GZ, et al. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab. BMC Cancer. 2020 Aug 20;20(1):783.
- Esteva FJ, Baranau YV, Baryash V, et al. Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial. Cancer Chemother Pharmacol. 2019 Oct;84(4):839–847.
- Rugo HS, Pennella EJ, Gopalakrishnan U, et al. Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. Breast. 2021 Aug;58:18–26.
- Saito Y, Tamaki S, Hasegawa H, et al. Safety evaluation of initial CT-P6 administration for 30 min during the switch from reference trastuzumab in maintenance infusion: a multicenter observational study. Biol Pharm Bull. 2021;44(4):474–477.
- Stebbing J, Baranau YV, Baryash V, et al. Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial. Breast Cancer Res Treat. 2021 Aug;188(3):631–640.
- Candelaria M, González DE, Delamain MT, et al. Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. Leuk Lymphoma. 2019 Dec;60(14):3375–3385.
- Jiang B, Ke X, Zhang Q, et al. Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20(+) B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study. Sci Rep. 2020;10(1):11676.
- Sharman JP, Liberati AM, Ishizawa K, et al. A randomized, double-blind, efficacy and safety study of PF-05280586 (a rituximab biosimilar) compared with rituximab reference product (MabThera(®)) in subjects with previously untreated CD20-positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL). Biodrugs. 2020 Apr;34(2):171–181.
- Shi Y, Song Y, Qin Y, et al. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. J Hematol Oncol. 2020 Apr 16;13(1):38.
- Toosi R, Mahmoudi H, Balighi K, et al. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study. J Dermatolog Treat. 2021 Feb;32(1):33–40.
- Reck M, Luft A, Bondarenko I, et al. A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. Lung Cancer. 2020 Aug;146:12–18.
- Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021 Jul;22(7):977–990.
- Rezvani H, Mortazavizadeh SM, Allahyari A, et al. Efficacy and safety of proposed bevacizumab biosimilar BE1040V in patients with metastatic colorectal cancer: a phase III, randomized, double-blind, noninferiority clinical trial. Clin Ther. 2020 May;42(5):848–859.
- Shi Y, Lei K, Jia Y, et al. Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: a multicenter, randomized, double-blinded, phase III trial. Cancer Commun (Lond). 2021 Sep;41(9):889–903.
- Thatcher N, Goldschmidt JH, Thomas M, et al. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res. 2019 Apr 1;25(7):2088–2095.
- Trukhin D, Poddubskaya E, Andric Z, et al. Efficacy, safety and immunogenicity of MB02 (Bevacizumab biosimilar) versus reference bevacizumab in advanced non-small cell lung cancer: a randomized, double-blind, phase III study (STELLA). Biodrugs. 2021 Jul;35(4):429–444.
- Egberts ACG, Meyboom RHB, van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance. Drug Saf. 2002 May 01;25(6):453–458.
- Vogel U, van Stekelenborg J, Dreyfus B, et al. Investigating overlap in signals from EVDAS, FAERS, and VigiBase(®). Drug Saf. 2020 Apr;43(4):351–362.
- Rahman MM, Alatawi Y, Cheng N, et al. Methodological considerations for comparison of brand versus generic versus authorized generic adverse event reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS). Clin Drug Investig. 2017 Dec;37(12):1143–1152.
- Tanni KA, Truong CB, Almahasis S, et al. Safety of marketed cancer supportive care biosimilars in the US: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS) database. BioDrugs. 2021 Mar;35(2):239–254.
- Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020 Jun;86:102017.
- Caldito NG, Shirani A, Salter A, et al. Adverse event profile differences between rituximab and ocrelizumab: findings from the FDA adverse event reporting database. Mult Scler. 2021 Jun;27(7):1066–1076.
- Wichelmann TA, Abdulmujeeb S, Ehrenpreis ED, et al. Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database. Aliment Pharmacol Ther. 2021 Nov;54(10):1290–1297.
- Ghosh P, Dewanji A. Effect of reporting bias in the analysis of spontaneous reporting data. Pharm Stat. 2015 Jan-Feb;14(1):20–25.
- Patel PK, King CR, Feldman SR. Biologics and biosimilars. J Dermatological Treat. 2015 Jul 4;26(4):299–302.